Longboard Pharmaceuticals Inc
NASDAQ:LBPH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Longboard Pharmaceuticals Inc
Total Liabilities
Longboard Pharmaceuticals Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Longboard Pharmaceuticals Inc
NASDAQ:LBPH
|
Total Liabilities
$21.8m
|
CAGR 3-Years
72%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Liabilities
$113.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Liabilities
$78.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
17%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Liabilities
$115.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Liabilities
$77.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Liabilities
$91.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
Longboard Pharmaceuticals Inc
Glance View
Nestled in the bustling biotech landscape, Longboard Pharmaceuticals Inc. has carved its niche by steering its focus toward developing transformative therapies for neurological diseases. Born from the strategic insights honed within Arena Pharmaceuticals, Longboard carries forward an unwavering commitment to unraveling the complexities of neurobiology. At its core, the company's research is laser-focused on advancing a robust pipeline, notably targeting conditions with high unmet needs such as epilepsy and other neuropsychiatric disorders. The cornerstone of their approach lies in leveraging cutting-edge science to target specific neurological pathways, thus fostering innovative drug candidates that hold the potential to redefine treatment paradigms. The financial engine of Longboard turns primarily on its potential to bring successful therapies to market. Like many firms in the biotech sector, its journey from the lab bench to patient bedside is fraught with substantial R&D investments, clinical trial navigation, and regulatory hurdles. The promise of substantial returns hinges on achieving significant breakthroughs, securing FDA approval, and eventually commercializing their therapies. Additional revenue streams might emerge through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical entities, which can provide both immediate funding and shared resources to propel their products forward. Ultimately, Longboard’s financial health is intertwined with its scientific progress and regulatory milestones, painting a picture of a company deeply embedded in the rhythms of innovation and impact-driven healthcare solutions.
See Also
What is Longboard Pharmaceuticals Inc's Total Liabilities?
Total Liabilities
21.8m
USD
Based on the financial report for Sep 30, 2024, Longboard Pharmaceuticals Inc's Total Liabilities amounts to 21.8m USD.
What is Longboard Pharmaceuticals Inc's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
72%
Over the last year, the Total Liabilities growth was 221%. The average annual Total Liabilities growth rates for Longboard Pharmaceuticals Inc have been 72% over the past three years .